Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Graybill, J. Herndon, W. Kniker, H. Levine (1980)
Ketoconazole treatment of chronic mucocutaneous candidiasis.Archives of dermatology, 116 10
Abstract To the Editor.— Ketoconazole is a newly approved oral agent effective against fungal pathogens.1 In vitro studies suggest that the drug impairs the synthesis of ergosterol, a vital component of fungal cell membranes. This process is unimportant in the metabolism of mammalian cells. Studies, involving more than 1,200 patients, have shown that the drug may have important toxic effects on the liver that, occasionally, can be fatal. Nausea and vomiting have been reported in 3% of the patients. According to the manufacturer, Janssen Pharmaceutica, New Brunswick, NJ, to date, no rashes have been reported from the drug, but pruritus is a complaint in 1.5% of the patients. We describe an exfoliative erythroderma occurring in a patient receiving ketoconazole therapy. Report of a Case.— A 48-year-old man who had a history of chronic renal failure was first seen by us for evaluation of an exfoliative erythroderma.He was in good References 1. Graybill JR, Herndon JH, Kniker WT, et al: Ketoconazole treatment of chronic mucocutaneous candidiasis . Arch Dermatol 1980;116:1137-1141.Crossref
Archives of Dermatology – American Medical Association
Published: Feb 1, 1983
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.